Connect with us


Prostate Cancer Treatment 225Ac-J591 Is Approved By The FDA

Avatar of Salman Ahmad



Prostate Cancer Treatment 225Ac-J591 Is Approved By The FDA

(CTN News) – The FDA Prostate Cancer has granted clearance to an investigational new drug (IND) application for 225Ac-J591 (CONV01-α), a prostate-specific membrane antigen-targeted monoclonal antibody under investigation for the treatment of advanced prostate cancer, said Convergent Therapeutics.1

Convergent Therapeutics’ co-founder and CEO, Philip Kantoff, MD, said, “Receiving clearance for our IND is a big deal.”1 “While we’ve already treated well over 100 prostate cancer patients for investigator INDs, this is a big deal.

This new IND will give us a fast track to phase 3 studies and let us develop CONV01-α as a monotherapy and in combination with other prostate cancer therapies.”

Convergent plans to start phase 2 clinical trials in 2024 and a registration program in 2025.

2 225Ac-J591 showed preliminary efficacy and safety across all dose levels in 177Lu-naive metastatic castration-resistant prostate cancer (mCRPC) patients in a phase 1 multi-dose, dose escalation study (NCT04506567) at the American Association of Prostate Cancer Research Annual Meeting in Orlando, Florida in 2023.

Specifically, 21 patients (95%) in the study who had a prostate-specific antigen (PSA) change experienced a drop in PSA. There were 14 patients (67%) who experienced a 50% decline and 6 (27%) who experienced a 90% decline.

At baseline and 12 weeks, we collected circulating tumor cell (CTC) samples from 13 of 21 patients. There were 5 patients with unfavorable CTC counts at baseline (5/7.5 mL). The CTC count of 10 patients remained favorable or converted from unfavorable to favorable at 12 weeks, 6 patients experienced a 50% decline, and 5 patients went from detectable to undetectable.

Each dose level of 225Ac-J591 was well tolerated. A dose-limiting toxicity (DLT) was not observed in either cohort. Cohort 3 had two DLTs, one grade 2 and one grade 3. Low-grade, non-hematologic adverse events most commonly reported included fatigue (95%), xerostomia (69%), and nausea (57%).

Adding to the news release, Neil Bander, MD, Convergent’s CSO, stated, “In phase 1/2 trials, patients experienced minimal adverse effects.” A perfect biodistribution method ensures alpha particles are delivered without immediate and significant salivary gland toxicity or delayed renal toxicity.

CONV01-α’s design targets tumor-killing radiation to malignant cells while reducing off-tumor effects and dose, increasing treatment safety and efficacy.”

This study included 24 patients predominantly with 177Lu-naive mCRPC. There was a median age of 73.5 years. ECOG performance status 0 to 2 and progressive mCRPC after treatment with an AR pathway inhibitor and chemotherapy were requirements for inclusion in the study.

Identifying the phase 2 dose for DLTs was the primary objective of the study. An exploratory efficacy measure was PSA decline, radiographic response rate, biochemical/radiographic progression-free survival, overall survival, CTC change, and patient reported outcomes, as well as safety and correlates (plasma and tissue genomics, PSMA imaging).


Patients With Breast Cancer May Be Able To Skip Chemotherapy

Salman Ahmad is a seasoned writer for CTN News, bringing a wealth of experience and expertise to the platform. With a knack for concise yet impactful storytelling, he crafts articles that captivate readers and provide valuable insights. Ahmad's writing style strikes a balance between casual and professional, making complex topics accessible without compromising depth.

Continue Reading

CTN News App

CTN News App

Recent News


compras monedas fc 24

Volunteering at Soi Dog

Find a Job

Jooble jobs

Free ibomma Movies